- Report
- January 2022
- 200 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- September 2024
- 82 Pages
Japan
From €3327EUR$3,500USD£2,795GBP
- Report
- October 2023
- 189 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- September 2020
- 65 Pages
Global
€1253EUR$1,318USD£1,053GBP
- Report
- June 2021
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- October 2019
- 128 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- April 2022
- 188 Pages
Global
From €3422EUR$3,600USD£2,875GBP
- Drug Pipelines
- March 2023
- 125 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- January 2024
- 138 Pages
United States
€3612EUR$3,800USD£3,035GBP
- Report
- January 2024
- 113 Pages
United States
€3327EUR$3,500USD£2,795GBP
- Report
- March 2023
- 30 Pages
Global
€11645EUR$12,250USD£9,783GBP
- Report
- April 2018
United States
From €7600EUR$7,995USD£6,385GBP
- Report
- April 2023
- 108 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- January 2022
- 220 Pages
Global
From €3529EUR$3,712USD£2,965GBP
Remicade is a biologic drug used to treat immune disorders such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Remicade is administered intravenously and is usually given in a series of three infusions over a period of several weeks.
Remicade is a major player in the immune disorders drugs market, with a wide range of indications and a long track record of safety and efficacy. It is one of the most widely prescribed biologic drugs in the world, and is used by millions of patients.
Companies in the Remicade market include Johnson & Johnson, Merck, Pfizer, AbbVie, and Amgen. Show Less Read more
